Abstract: The invention relates to a HLA-B27 Fc open conformer or a HLA-B27 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B27 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B27 Fc open conformer and immune checkpoint inhibitors.

Abstract: The invention relates to the use of an extracellular domain of Nogo selected from Nogo-A delta 20 and Nogo-66 for the treatment of glioblastoma, particularly by intravenous or intrathecal administration.

Abstract: The invention relates to a method for selecting an expressed sequence from a library, comprising the following steps: Each of a plurality of eukaryotic cells comprising a cell wall comprises a nucleic acid sequence member of a library, which is expressed as a target membrane protein in said eukaryotic cells. The cell wall of the cells is permeabilized. The permeabilized cells are labeled with a ligand capable of binding to the target membrane protein. The ligand bears a detectable label. A subset of the labelled cells is selected as a function of detectable label present. Finally, an expressed nucleic acid sequence is isolated from said selection of cells in an isolation step.

Abstract: The invention relates to a method for determining a biomarker on single cell level by counting a first portion of a cell sample, subjecting said first portion to conditions whereby the biomarker is fragmented, adding to a known number n(k) of labelled biomarker fragments, measuring a first and a second parameter of said first portion, wherein said first parameter corresponds to the amount of said biomarker fragment and said second parameter corresponds to the amount of said labelled biomarker fragment yielding a biomarker fragment value, v(u), and a labelled biomarker fragment value v(k), respectively, and relating v(u) and v(k) with n(k) and c(1), thereby determining an average number of biomarker molecules per cell, m(u), of said first portion.

Abstract: A method for estimating a brain activity response following a stimulus of a person comprises the steps: providing a usage data set of the person from a personal device used by said person, wherein at least one usage attribute is associated to said usage data set, wherein attribute data is associated to each of the at least one usage attribute, providing a computational inference model, generated from a plurality of brain activity data sets and a plurality of usage data sets, wherein each brain activity data set comprises data derived from a brain activity response following a sensory stimulus, submitting the attribute data of each of the at least one usage attributes to said computational inference model, estimating a brain activity response following a sensory stimulus of said person by evaluating said computational inference model for the submitted attribute data. The method is useful to determine, for example the influence of intensive touch pad usage (of a smartphone) on somatosensory evoked potentials.

Abstract: A dynamic field camera arrangement for monitoring electromagnetic field behavior in a spatial region comprises a main magnetic field and a radiofrequency (RF) field limited to a first RF band, particularly in an MRI or NMR apparatus. The arrangement comprises a magnetic field detector set comprising a plurality of low-frequency magnetic field detectors, each one of said magnetic field detectors comprising a magnetic resonance (MR) active substance, means for pulsed MR excitation of said substance and means for receiving an MR signal generated by said substance, wherein said pulsed excitation and said MR detector signal is in a second RF band that does not overlap said first RF band. The MR signal receiving means comprise a first RF filter which suppresses RF signal from said first RF band and transmits RF signal from said second RF band.

Abstract: The invention relates to a medical implant, comprising an expandable structure (100) which is designed to be expanded from a crimped state into an expanded state, wherein the structure (100) forms a tubular scaffolding in the expanded state, and wherein the structure (100) comprises a plurality of first struts (101) arranged along a periphery of the structure in said expanded state. According to the invention, the first struts (101) each comprise a recess (O), wherein the medical implant (1) further comprises a sealing member (200) arranged in said recesses (O), wherein said sealing member (200) is formed annularly in said expanded state.

Abstract: The present invention is directed to a method of producing a tissue graft, comprising at least steps of providing a gel, seeding the gel with cells of at least a first and/or cells of a second type, and culturing of the cells of the first and/or cells of the second type in said gel until the formation of at least one first biostructure in the gel by the cells of the first type and/or the cells of the second type.

Abstract: A method of observing axial magnetization (Mz) in an object (O) located in a main magnetic field (B0) comprises the step of determining magnetic field intensity (Bp) in at least one magnetic field probe (P) arranged in the neighborhood of the object. The magnetic field probe comprises a magnetic resonance (MR) active substance, means for pulsed MR excitation of the substance and means for receiving an MR signal generated by said substance.

Abstract: The present invention relates to a method for tracking a position of at least one keypoint in an image of an object moving relative to an optical sensor, wherein light reflected from the object (12) is detected so as to generate an image of the object, and wherein a position of at least one keypoint (Kj) in said image is detected and updated using temporal contrast events (Ev) of the optical sensor. The invention also relates to a corresponding computer program and device.

Abstract: The invention relates to a device for measuring the concentration of an analyte in the blood or tissue of a an animal or a human, particularly a premature infant, wherein for measuring said concentration the device comprises a means (30) comprising at least a first and a second permeability with respect to said analyte, wherein the first permeability for said analyte differs from the second permeability for the analyte. Further, the invention relates to a corresponding method.

Abstract: The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of IL-1?, IL-1 receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of IL-1?, IL-1 receptor type 1, IL-1 receptor type 2, NLRP3, ASC and Caspase-1. Similarly, an interfering RNA or an antisense modulator of gene expression of IL-1?, I L-1? receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B are provided for the prevention or treatment of acne.

Abstract: The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)?7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)?1×10?4 s?1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.

Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.

Abstract: The invention relates to compounds characterized by a general formula (1), wherein X is a group described by a general formula —Kp—Fl—Kq—, wherein Fl is —C(?O)—, —C(?S)—, with l being 0 or 1, Kp is a Cp-alkyl with p being 0, 1, 2, 3 or 4, Kq is a Cq-alkyl with q being 0, 1, 2, 3 or 4, and wherein n of R1n is 0, 1, 2, 3, 4 or 5, and each R1 independently from any other R1 is —C(?O)OR2, —C(?O)NR22, —C(?O)SR2, —C(?S)OR2, —C(NH)NR22, CN4H2, —NR22, —C(?O)R2, —C(?S)R2, —OR2, —SR2, —CF3, —OCF3, —SCF3, —SOCF3, —SO2CF3, —CN, —NO2, —F, —Cl, —Br or —I, with each R2 independently from any other R2 being a hydrogen or C1-C4 alkyl, and wherein OM is an organometallic compound independently selected from the group of an unsubstituted or substituted metal sandwich compound, an unsubstituted or substituted half metal sandwich compound or a metal carbonyl compound and their use in a method for treatment of infections by helminths.

Abstract: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules.

Abstract: The invention relates to a photoarray (1), comprising: a plurality of cells (10), wherein each of said cells (10) comprises a means (20)that is configured to generate a photocurrent (I) being proportional to the intensity (L) of the light impinging on the respective cell (10), and wherein each of said cells (10) comprises a change detection circuit (100) connected to the respective means (20) for generating the photocurrent (I), which change detection circuit (100) is configured to generate an output signal merely in case a change event occurs at which said intensity (L) changes by a threshold amount (T, T?) since the preceding change event from the respective cell (10). According to the invention said means (20) for generating said photocurrent (I) is additionally also used to estimate the magnitude of the said photocurrent (I) being a measure of the brightness of the light at the respective cell (10).

Abstract: The invention relates to octadentate ligands of a general formula R1-D-X-D-X-D-X-D-E-R2, wherein D is C(O)N(OH) or N(OH)C(O), pyrimidinone or pyridinone, each X independently of any other X is a saturated or partially unsaturated, substituted or unsubstituted linker comprising 8-11 atoms selected from any of N, C, O; R1 is alkyl, cycloalkyl, arene, or heteroarene, E is a saturated or partially unsaturated, substituted or unsubstituted chain comprising 1-50 atoms and R2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging.

Abstract: An anchor element serves for knotless fixing of a tissue to a bone by at least one suture threaded through the anchor element. A body of that anchor element has an outer surface with projections. A transverse bore is arranged in a distal end section of the body for receiving a threading passing therethrough. A clamp element serves for clamping the suture threaded transversely through the bore. The clamping element has a portion arranged within the body and is movable within the body towards that transverse bore.

Abstract: The invention comprises a compound characterized by a general formula (1), wherein X is a group described by a general formula —Kp—Fl—Kq—, wherein Fl is —C(?O)—, —C(?S)—, with l being 0 or 1, Kp is a Cp-alkyl with p being 0, 1, 2, 3 or 4, Kq is a Cq-alkyl with q being 0, 1, 2, 3 or 4, and wherein Z is a group described by a general formula —Kr—Fi—Kt—, wherein Fi —O—, —S—, —O—C(?O)—, —O—C(?S)—, —S—C(?O)— or —NH—(C?O)— with i being 0 or 1, Kr is a Cr-alkyl with r being 0, 1, 2, 3 or 4, Kt is a Ct-alkyl with t being 0, 1, 2, 3 or 4, wherein each OM is an organometallic compound independently selected from each other from the group of an unsubstituted or substituted metal sandwich compound, an unsubstituted or substituted half metal sandwich compound or a metal carbonyl compound and their use.